Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Parasitology ; : 1-7, 2022 Jan 26.
Article in English | MEDLINE | ID: mdl-35189998

ABSTRACT

Although Nematodirus battus is a serious threat to the health and survival of young lambs, there are few options to control this parasite. Bayesian Monte Carlo Markov Chain modelling with a zero-inflated Poisson distribution was used to estimate the heritability of egg counts in both June and July for each of five consecutive cohorts of 200 Scottish Blackface lambs. In one of the 10 analyses, the results failed the diagnostic tests. In seven of the analyses, there was no convincing evidence that the variation in egg counts was heritable. In the 2 years of high infection, the heritability was approximately 0.4 in June but the estimates lacked precision and the 95% highest posterior density credible intervals ranged from just above zero to 0.7. Selective breeding for resistance to N. battus will be difficult because genetically resistant or susceptible lambs cannot be consistently identified by phenotypic markers.

2.
Article in English | MEDLINE | ID: mdl-33597311

ABSTRACT

SUMMARY: An 11-year-old girl presented with acute lower limb weakness, dehydration, hypernatraemia and secondary rhabdomyolysis on a background of an 8-month history of polyuria. Radiological investigations revealed a suprasellar tumour which was diagnosed on biopsy as a non-metastatic germinoma. Further endocrinological investigations confirmed panhypopituitarism and she commenced desmopressin, hydrocortisone and thyroxine. Her chemotherapeutic regime consisted of etoposide, carboplatin and ifosfamide, the latter of which required 4 litres of hyperhydration therapy daily. During the first course of ifosfamide, titration of oral desmopressin was trialled but this resulted in erratic sodium control leading to disorientation. Based on limited literature, we then trialled an arginine-vasopressin (AVP) infusion. A sliding scale was developed to adjust the AVP dose, with an aim to achieve a urine output of 3-4 mL/kg/h. During the second course of ifosamide, AVP infusion was commenced at the outset and tighter control of urine output and sodium levels was achieved. In conclusion, we found that an AVP infusion during hyperhydration therapy was required to achieve eunatraemia in a patient with cranial diabetes insipidus. Developing an AVP sliding scale requires individual variation; further reports/case series are required to underpin practice. LEARNING POINTS: Certain chemotherapeutic regimens require large fluid volumes of hyperhydration therapy which can result in significant complications secondary to rapid serum sodium shifts in patients with diabetes insipidus. The use of a continuous AVP infusion and titrating with a sliding scale is more effective than oral desmopressin in regulating plasma sodium and fluid balance during hyperhydration therapy. No adverse effects were found in our patient using a continuous AVP infusion. Adjustment of the AVP infusion rate depends on urine output, fluid balance, plasma sodium levels and sensitivity/response of the child to titrated AVP doses.

3.
Evol Bioinform Online ; 16: 1176934320962521, 2020.
Article in English | MEDLINE | ID: mdl-33100828

ABSTRACT

Parasitic cysteine proteases are involved in parasite stage transition, invasion of host tissues, nutrient uptake, and immune evasion. The cysteine protease cathepsin F is the most abundant protein produced by fourth-stage larvae (L4) of the nematode Teladorsagia circumcincta, while its transcript is only detectable in L4 and adults. T. circumcincta cathepsin F is a recently evolved cysteine protease that does not fall clearly into either of the cathepsin L or F subfamilies. This protein exhibits characteristics of both cathepsins F and L, and its phylogenetic relationship to its closest homologs is distant, including proteins of closely related nematodes of the same subfamily.

4.
Transbound Emerg Dis ; 66(5): 2058-2066, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31140207

ABSTRACT

A novel Group A rotavirus, first identified clinically in racing, feral and fancy pigeons in Western Australia, had spread throughout Australia by March 2017. In December 2016, the putative index case of rotavirus in racing pigeons in the state of Victoria was confirmed at a regional bird sale, with rapid spread to peri-urban Melbourne, the capital city. A survey sent to approximately 400 Victorian pigeon fanciers identified eight (of 85 respondents) with a confirmed rotavirus infection in their loft(s). If a fancier had purchased live birds, either from the regional sale or from another source, there was a 13%-38% increased likelihood of the loft subsequently being confirmed rotavirus-positive. An increased loft-level risk of rotavirus was also positively associated with the number of neighbouring lofts within a 5-km radius of a home loft. It was concluded that rotavirus was primarily transmitted beyond the Victorian index case through the movement of live birds into a loft, either deliberately through bird purchase and/or inadvertently through the entry of pigeons from neighbouring lofts. As pigeon racing inherently requires consistent contact between birds from different lofts, vaccination is recommended as a primary method of rotavirus control in this unique industry.


Subject(s)
Bird Diseases/virology , Columbidae/virology , Rotavirus Infections/epidemiology , Rotavirus Infections/veterinary , Rotavirus/isolation & purification , Animals , Disease Outbreaks/veterinary , Industry , Risk Factors , Rotavirus/classification , Victoria/epidemiology , Western Australia
5.
Parasit Vectors ; 10(1): 503, 2017 Oct 19.
Article in English | MEDLINE | ID: mdl-29052521

ABSTRACT

BACKGROUND: Canids are definitive hosts of the apicomplexan parasite Neospora caninum, the leading cause of abortion in cattle worldwide. For horizontal transmission from canids to occur, oocysts of N. caninum must be shed by the definitive host into the environment of susceptible intermediate hosts such as cattle. The purpose of this study was to determine the prevalence of N. caninum in canids in Victoria, Australia's leading dairy producing state. RESULTS: Neospora-like oocysts were observed in 8% (18/234) of faecal samples from wild dogs, domestic dogs and red foxes from Victoria, Australia. However, none tested positive for N. caninum DNA using a quantitative PCR. In a separate sample population, blood sera from 483 domestic dogs were tested for anti-N. caninum antibodies using competitive ELISA. A subset of cELISA samples were re-tested using indirect fluorescence antibody test (IFAT). A seroprevalence of 29.8% (144/483; 95% CI: 11.7-47.8%) was calculated when using cELISA; whereas it was 32.9% (27/80; 95% CI: 15.8-51.8%) using IFAT. Potential risk factors were evaluated using univariable analyses and then assessed in separate multivariable models. Using 'aged' dogs as a reference, the seroprevalence of 'adolescent' and 'adult' dogs was 88% (P = 0.05) and 91% (P = 0.08), respectively, indicating seroprevalence increases with age. There was a 19% higher likelihood of infection in rural locations (P = 0.10) relative to urban areas. Jack Russell Terriers had a 22% higher risk of a cELISA-positive result (P = 0.05) regardless of geographical location, age or sex. CONCLUSION: These results demonstrate that exposure to N. caninum in domestic dogs is widespread in Victoria, although faecal oocyst shedding is infrequent. Our results indicate increased N. caninum seroprevalance status in dogs over the past two decades. The results imply that dogs get either exposed to the infected meat more frequently or that vertical dam to foetus transmission is more frequent than previously thought. Our study calls for re-evaluation of historical N. caninum seroprevalance studies, because the attitude to dog diet changes.


Subject(s)
Antibodies, Protozoan/blood , Coccidiosis/veterinary , Dog Diseases/epidemiology , Neospora/immunology , Animals , Animals, Wild/parasitology , Cattle , Coccidiosis/epidemiology , Coccidiosis/immunology , Coccidiosis/transmission , Dog Diseases/immunology , Dog Diseases/parasitology , Dog Diseases/transmission , Dogs , Enzyme-Linked Immunosorbent Assay , Feces/parasitology , Female , Foxes/parasitology , Male , Neospora/genetics , Neospora/isolation & purification , Oocysts/genetics , Oocysts/isolation & purification , Polymerase Chain Reaction , Pregnancy , Rural Population , Seroepidemiologic Studies , Time Factors
6.
J Immunol ; 199(4): 1342-1352, 2017 08 15.
Article in English | MEDLINE | ID: mdl-28710254

ABSTRACT

Ocular infection with HSV causes a chronic T cell-mediated inflammatory lesion in the cornea. Lesion severity is affected by the balance of different CD4 T cell subsets, with greater severity occurring when the activity of regulatory T cells (Tregs) is compromised. In this study, fate-mapping mice were used to assess the stability of Treg function in ocular lesions. We show that cells that were once Foxp3+ functional Tregs may lose Foxp3 and become Th1 cells that could contribute to lesion expression. The instability primarily occurred with IL-2Rlo Tregs and was shown, in part, to be the consequence of exposure to IL-12. Lastly, in vitro-generated induced Tregs (iTregs) were shown to be highly plastic and capable of inducing stromal keratitis when adoptively transferred into Rag1-/- mice, with 95% of iTregs converting into ex-Tregs in the cornea. This plasticity of iTregs could be prevented when they were generated in the presence of vitamin C and retinoic acid. Importantly, adoptive transfer of these stabilized iTregs to HSV-1-infected mice prevented the development of stromal keratitis lesions more effectively than did control iTregs. Our results demonstrate that CD25lo Treg and iTreg instability occurs during a viral immunoinflammatory lesion and that its control may help to avoid lesion chronicity.


Subject(s)
Cell Plasticity , Cornea/immunology , Cornea/pathology , Herpesvirus 1, Human/immunology , Keratitis, Herpetic/immunology , T-Lymphocytes, Regulatory/immunology , Th1 Cells/immunology , Adoptive Transfer , Animals , Ascorbic Acid/pharmacology , CD4-Positive T-Lymphocytes/immunology , Cell Differentiation , Cornea/virology , Female , Forkhead Transcription Factors/analysis , Homeodomain Proteins/genetics , Interleukin-12/immunology , Interleukin-12/metabolism , Interleukin-2 Receptor alpha Subunit/genetics , Interleukin-2 Receptor alpha Subunit/immunology , Keratitis, Herpetic/physiopathology , Keratitis, Herpetic/virology , Lymphocyte Activation , Mice , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/physiology , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/physiology , Th1 Cells/physiology , Tretinoin/pharmacology
7.
Proc Natl Acad Sci U S A ; 113(8): 2235-40, 2016 Feb 23.
Article in English | MEDLINE | ID: mdl-26858424

ABSTRACT

Plasmodium infections result in clinical presentations that range from asymptomatic to severe malaria, resulting in ∼1 million deaths annually. Despite this toll on humanity, the factors that determine disease severity remain poorly understood. Here, we show that the gut microbiota of mice influences the pathogenesis of malaria. Genetically similar mice from different commercial vendors, which exhibited differences in their gut bacterial community, had significant differences in parasite burden and mortality after infection with multiple Plasmodium species. Germfree mice that received cecal content transplants from "resistant" or "susceptible" mice had low and high parasite burdens, respectively, demonstrating the gut microbiota shaped the severity of malaria. Among differences in the gut flora were increased abundances of Lactobacillus and Bifidobacterium in resistant mice. Susceptible mice treated with antibiotics followed by yogurt made from these bacterial genera displayed a decreased parasite burden. Consistent with differences in parasite burden, resistant mice exhibited an elevated humoral immune response compared with susceptible mice. Collectively, these results identify the composition of the gut microbiota as a previously unidentified risk factor for severe malaria and modulation of the gut microbiota (e.g., probiotics) as a potential treatment to decrease parasite burden.


Subject(s)
Gastrointestinal Microbiome , Malaria/microbiology , Animals , Anti-Bacterial Agents/therapeutic use , Bifidobacterium/isolation & purification , Bifidobacterium/physiology , Gastrointestinal Microbiome/immunology , Gastrointestinal Microbiome/physiology , Germ-Free Life , Host-Parasite Interactions/immunology , Humans , Lactobacillus/isolation & purification , Lactobacillus/physiology , Malaria/parasitology , Malaria/therapy , Mice , Mice, Inbred C57BL , Parasite Load , Plasmodium yoelii , Probiotics/therapeutic use
8.
Curr Opin Plant Biol ; 26: 32-6, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26116973

ABSTRACT

Root microbiomes are formed from diverse microbial soil settings with extraordinary consistency, suggesting both defined mechanisms of assembly and specific microbial activity. Recent improvements in sequencing technologies, data analysis techniques, and study design, allow definition of the microbiota within these intimate and important relationships with increasing accuracy. Comparing datasets provides powerful insights into the overlap of plant microbiomes, as well as the impacts of surrounding plants and microbes on root microbiomes and long-term soil conditioning. Here we address how recent studies tease apart the impact of various biotic interactions, including: plant-plant, plant-microbe, and microbe-microbe on root microbiome composition.


Subject(s)
Microbiota/physiology , Plant Roots/microbiology , Soil Microbiology
9.
J Immunol ; 194(2): 697-708, 2015 Jan 15.
Article in English | MEDLINE | ID: mdl-25505280

ABSTRACT

Plasmodium remains a major pathogen causing malaria and impairing defense against other infections. Defining how Plasmodium increases susceptibility to heterologous pathogens may lead to interventions that mitigate the severity of coinfections. Previous studies proposed that reduced T cell responses during coinfections are due to diminished recruitment of naive T cells through infection-induced decreases in chemokine CCL21. We found that, although Listeria infections reduced expression of CCL21 in murine spleens, lymphocytic choriomeningitis virus (LCMV)-specific T cell responses were not impaired during Listeria + LCMV coinfection, arguing against a major role for this chemokine in coinfection-induced T cell suppression. In our experiments, Plasmodium yoelii infection led to a reduced CD8(+) T cell response to a subsequent Listeria infection. We propose an alternative mechanism whereby P. yoelii suppresses Listeria-specific T cell responses. We found that Listeria-specific T cells expanded more slowly and resulted in lower numbers in response to coinfection with P. yoelii. Mathematical modeling and experimentation revealed greater apoptosis of Listeria-specific effector T cells as the main mechanism, because P. yoelii infections did not suppress the recruitment or proliferation rates of Listeria-specific T cells. Our results suggest that P. yoelii infections suppress immunity to Listeria by causing increased apoptosis in Listeria-specific T cells, resulting in a slower expansion rate of T cell responses.


Subject(s)
Coinfection/immunology , Immunity, Cellular , Listeria monocytogenes/immunology , Listeriosis/immunology , Malaria/immunology , Plasmodium yoelii/immunology , T-Lymphocytes/immunology , Animals , Apoptosis/immunology , Chemokine CCL21/genetics , Chemokine CCL21/immunology , Coinfection/genetics , Coinfection/microbiology , Coinfection/parasitology , Coinfection/pathology , Listeriosis/genetics , Listeriosis/parasitology , Listeriosis/pathology , Malaria/genetics , Malaria/microbiology , Malaria/pathology , Mice , Mice, Transgenic
10.
J Am Coll Cardiol ; 63(22): 2421-8, 2014 Jun 10.
Article in English | MEDLINE | ID: mdl-24727254

ABSTRACT

OBJECTIVES: This study sought to test 2 hypotheses: 1) fibroblast growth factor (FGF)-23 identifies patients with stable ischemic heart disease (SIHD) at high risk of cardiovascular events independent of clinical factors, renal function, and established cardiovascular biomarkers; and 2) FGF-23 identifies patients who derive greater clinical benefit from angiotensin-converting enzyme inhibitor therapy. BACKGROUND: FGF-23 is an endocrine regulator of mineral metabolism and markedly elevated levels are associated with cardiovascular events in patients with chronic kidney disease. Data in patients with SIHD are more sparse. METHODS: FGF-23 levels were measured in 3,627 patients with SIHD randomly assigned to trandolapril or placebo within the PEACE (Prevention of Events With Angiotensin-Converting Enzyme) trial and followed up for a median of 5.1 years. RESULTS: After adjustment for clinical risk predictors, left ventricular ejection fraction, markers of renal function, and established cardiovascular biomarkers, FGF-23 concentration was independently associated with an increased risk of cardiovascular death or heart failure among patients allocated to placebo (quartile 4 hazard ratio: 1.73; 95% confidence interval, 1.09 to 2.74; p = 0.02) and significantly improved metrics of discrimination. Furthermore, among patients in the top quartile of FGF-23 levels, trandolapril significantly reduced cardiovascular death or incident heart failure (hazard ratio: 0.45; 95% confidence interval: 0.28 to 0.72), whereas there was no clinical benefit in the remaining patients (hazard ratio: 1.07; 95% confidence interval: 0.75 to 1.52; p interaction = 0.0039). This interaction was independent of and additive to stratification based on renal function. CONCLUSIONS: Elevated levels of FGF-23 are associated with cardiovascular death and incident heart failure in patients with SIHD and identify patients who derive significant clinical benefit from angiotensin-converting enzyme inhibitor therapy regardless of renal function. (Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy [PEACE]: NCT00000558).


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Fibroblast Growth Factors/blood , Indoles/therapeutic use , Myocardial Ischemia/blood , Myocardial Ischemia/drug therapy , Aged , Biomarkers/blood , Cardiovascular Diseases/etiology , Female , Fibroblast Growth Factor-23 , Humans , Male , Middle Aged , Myocardial Ischemia/complications , Prognosis , Risk
11.
Clin Cardiol ; 37(3): 160-6, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24452727

ABSTRACT

BACKGROUND: The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described. HYPOTHESIS: We hypothesized that Q waves would be associated with less successful reperfusion and increased cardiovascular events. METHODS: In the CLARITY-TIMI 28 trial, 3491 STEMI patients treated with fibrinolysis were randomized to clopidogrel or placebo. Electrocardiograms were evaluated for STRes post-fibrinolysis and the presence of pathologic Q waves during the index hospitalization in 3322 patients. RESULTS: Q waves were identified in 2045 patients (61.6%) prior to discharge and were associated with increased odds of congestive heart failure (CHF) (adjusted odds ratio [ORadj ]: 2.10, P = 0.002) or the composite of cardiovascular death/CHF at 30 days (ORadj : 2.08, P ≤ 0.001). Q waves were associated with lower odds of Thrombolysis in Myocardial Infarction [TIMI] flow grade 2 to 3 (ORadj : 0.78, P = 0.028), TIMI myocardial perfusion grade 3 (ORadj : 0.83, P = 0.029), and complete STRes at 90 minutes (ORadj : 0.80, P = 0.030). Patients with both a Q wave and incomplete STRes 90 minutes after fibrinolysis were at higher risk for cardiovascular death or CHF (11.1%) than patients with no Q wave and at least partial STRes (1.9%). Overall, clopidogrel tended to be equally or more effective in patients without Q waves compared to those with Q waves. CONCLUSIONS: Among STEMI patients treated with fibrinolysis, evaluating for Q waves prior to discharge is a simple method of assessing for less successful reperfusion and an increased risk of adverse 30-day cardiovascular outcomes. The combination of Q waves and 90-minute STRes allows additional risk refinement.


Subject(s)
Electrocardiography , Heart Failure/epidemiology , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Myocardial Reperfusion/methods , Platelet Aggregation Inhibitors/therapeutic use , Aged , Aspirin/therapeutic use , Clopidogrel , Coronary Angiography , Coronary Circulation , Coronary Thrombosis/diagnostic imaging , Creatine Kinase, MB Form/blood , Female , Hospitalization , Humans , Male , Middle Aged , Prognosis , Risk Assessment/methods , Sex Factors , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use
12.
Obes Surg ; 24(2): 292-8, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24092517

ABSTRACT

Research has shown that some bariatric patients overestimate post-surgical exercise levels, while others struggle with negative cognitions and follow-through on intentions to exercise; however, little exists on specific barriers affecting bariatric patients' post-surgical exercise behaviors. Considering that regular exercise is a predictor of weight loss maintenance, further research is warranted. Survey methodology was utilized to assess post-operative exercise barriers as well as beneficial post-surgical exercise services among a sample of bariatric patients solicited from an online support website. Qualitative assessment of responses was completed using inductive content analysis. Higher-order themes for exercise barriers included internal, external, and no barriers; generic categories determined for internal barriers included motivational and physical barriers. Of the participants, 78% reported at least one internal motivational barrier, and the most frequently reported subcategorical barrier was time (28%); physical barriers were reported related to surgery (9%) or other chronic conditions (19%). Higher-order themes for exercise services included positive descriptions such as benefits from exercise prescription as well as the importance of facilities and individuals, while negative descriptions included no services available or services that were unhelpful. Participants cited the benefit of community-based facilities, so providers might consider partnering with local professionals to deliver exercise services. Staff should be aware of physical barriers specific to bariatric populations including issues with post-surgical stamina and chronic comorbid conditions in order to provide appropriate exercise prescription. In addition, as motivational and time barriers occur frequently, providers should be well-trained on how to help patients overcome these impediments to exercise maintenance.


Subject(s)
Bariatric Surgery , Exercise , Guideline Adherence , Health Behavior , Obesity, Morbid/psychology , Weight Loss , Aftercare , Comorbidity , Cross-Sectional Studies , Female , Humans , Male , Motivation , Obesity, Morbid/surgery , Patient Compliance/statistics & numerical data , Postoperative Period , Qualitative Research , Time Factors , Weight Gain
13.
J Am Coll Cardiol ; 63(6): 520-7, 2014 Feb 18.
Article in English | MEDLINE | ID: mdl-24161323

ABSTRACT

OBJECTIVES: The purpose of this study was to assess the prognostic utility of lipoprotein(a) [Lp(a)] in individuals with coronary artery disease (CAD). BACKGROUND: Data regarding an association between Lp(a) and cardiovascular (CV) risk in secondary prevention populations are sparse. METHODS: Plasma Lp(a) was measured in 6,708 subjects with CAD from 3 studies; data were then combined with 8 previously published studies for a total of 18,978 subjects. RESULTS: Across the 3 studies, increasing levels of Lp(a) were not associated with the risk of CV events when modeled as a continuous variable (odds ratio [OR]: 1.03 per log-transformed SD, 95% confidence interval [CI]: 0.96 to 1.11) or by quintile (Q5:Q1 OR: 1.05, 95% CI: 0.83 to 1.34). When data were combined with previously published studies of Lp(a) in secondary prevention, subjects with Lp(a) levels in the highest quantile were at increased risk of CV events (OR: 1.40, 95% CI: 1.15 to 1.71), but with significant between-study heterogeneity (p = 0.001). When stratified on the basis of low-density lipoprotein (LDL) cholesterol, the association between Lp(a) and CV events was significant in studies in which average LDL cholesterol was ≥130 mg/dl (OR: 1.46, 95% CI: 1.23 to 1.73, p < 0.001), whereas this relationship did not achieve statistical significance for studies with an average LDL cholesterol <130 mg/dl (OR: 1.20, 95% CI: 0.90 to 1.60, p = 0.21). CONCLUSIONS: Lp(a) is significantly associated with the risk of CV events in patients with established CAD; however, there exists marked heterogeneity across trials. In particular, the prognostic value of Lp(a) in patients with low cholesterol levels remains unclear.


Subject(s)
Acute Coronary Syndrome/blood , Coronary Artery Disease/blood , Lipoprotein(a)/blood , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/therapy , Biomarkers/blood , Coronary Artery Disease/diagnosis , Coronary Artery Disease/drug therapy , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Prognosis , Randomized Controlled Trials as Topic , Risk Assessment , Secondary Prevention
14.
J Cardiovasc Pharmacol Ther ; 18(6): 555-9, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24064010

ABSTRACT

BACKGROUND: The well-described morning peak in the onset of acute coronary syndromes has been partly attributed to increased platelet activity upon arising. It has been suggested that stent thrombosis (ST) exhibits a similar pattern. We assessed whether a diurnal variation in ST occurs, and whether more robust antiplatelet therapy with prasugrel (vs clopidogrel) can attenuate a morning excess. METHODS AND MATERIALS: Patients from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial (N = 13 608) with adjudicated ST classified per the Academic Research Consortium definitions of definite (N = 135) and probable (N = 27) were grouped into prespecified 8-hour intervals by time of onset: early (6 am-2 pm), late-day (2 pm-10 pm), and overnight (10 pm-6 am). We compared the rates per 1000 patients of ST across time intervals and stratified by treatment and stent type. RESULTS: A diurnal variation in definite/probable ST was observed with rates of 6.5, 3.7, and 2.1 for early, late-day, and overnight intervals, respectively (P < .001), per 1000 patients treated. A sensitivity analysis excluding periprocedural acute-ST (<24 hours after index percutaneous coronary intervention [PCI]) resulted in similar findings (5.2, 2.5, and 1.8 per 1000, P < .001). The circadian variation in ST was observed in patients on clopidogrel (9.7, 4.8, and 3.1 per 1000, P < .001) with the highest rate of ST early in the day. Patients on prasugrel also demonstrated a circadian variation with particularly low rates of overnight ST (3.4, 3.0, and 1.1 per 1000, P = .020). CONCLUSIONS: In TRITON-TIMI 38 trial, the timing of ST exhibited a significant diurnal variation similar to that seen with onset of other acute coronary syndromes. ST occurred less frequently among patients randomized to prasugrel compared to clopidogrel with the greatest absolute reduction (6.2 per 1000 patients) in events earlier in the day when platelet activity is known to be highest.


Subject(s)
Piperazines/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Thiophenes/therapeutic use , Thrombosis/prevention & control , Ticlopidine/analogs & derivatives , Acute Coronary Syndrome/physiopathology , Acute Coronary Syndrome/therapy , Aged , Circadian Rhythm/physiology , Clopidogrel , Double-Blind Method , Female , Humans , Male , Middle Aged , Prasugrel Hydrochloride , Stents , Thrombosis/physiopathology , Ticlopidine/therapeutic use , Time Factors , Treatment Outcome
15.
J Am Heart Assoc ; 2(1): e003269, 2013 Jan 29.
Article in English | MEDLINE | ID: mdl-23525425

ABSTRACT

BACKGROUND: Although there are multiple methods of risk stratification for ST-elevation myocardial infarction (STEMI), this study presents a prospectively validated method for reclassification of patients based on in-hospital events. A dynamic risk score provides an initial risk stratification and reassessment at discharge. METHODS AND RESULTS: The dynamic TIMI risk score for STEMI was derived in ExTRACT-TIMI 25 and validated in TRITON-TIMI 38. Baseline variables were from the original TIMI risk score for STEMI. New variables were major clinical events occurring during the index hospitalization. Each variable was tested individually in a univariate Cox proportional hazards regression. Variables with P<0.05 were incorporated into a full multivariable Cox model to assess the risk of death at 1 year. Each variable was assigned an integer value based on the odds ratio, and the final score was the sum of these values. The dynamic score included the development of in-hospital MI, arrhythmia, major bleed, stroke, congestive heart failure, recurrent ischemia, and renal failure. The C-statistic produced by the dynamic score in the derivation database was 0.76, with a net reclassification improvement (NRI) of 0.33 (P<0.0001) from the inclusion of dynamic events to the original TIMI risk score. In the validation database, the C-statistic was 0.81, with a NRI of 0.35 (P=0.01). CONCLUSIONS: This score is a prospectively derived, validated means of estimating 1-year mortality of STEMI at hospital discharge and can serve as a clinically useful tool. By incorporating events during the index hospitalization, it can better define risk and help to guide treatment decisions.


Subject(s)
Decision Support Techniques , Myocardial Infarction/drug therapy , Thrombolytic Therapy , Aged , Female , Humans , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/complications , Myocardial Infarction/diagnosis , Myocardial Infarction/mortality , Odds Ratio , Patient Discharge , Predictive Value of Tests , Proportional Hazards Models , Prospective Studies , Reproducibility of Results , Risk Assessment , Risk Factors , Thrombolytic Therapy/adverse effects , Thrombolytic Therapy/mortality , Time Factors , Treatment Outcome
16.
Circulation ; 125(2): 233-40, 2012 Jan 17.
Article in English | MEDLINE | ID: mdl-22179538

ABSTRACT

BACKGROUND: Circulating biomarkers can offer insight into subclinical cardiovascular stress and thus have the potential to aid in risk stratification and tailoring of therapy. METHODS AND RESULTS: We measured plasma levels of 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and copeptin, in 3717 patients with stable coronary artery disease and preserved left ventricular ejection fraction who were randomized to trandolapril or placebo as part of the Prevention of Events With Angiotensin Converting Enzyme (PEACE) trial. After adjustment for clinical cardiovascular risk predictors and left ventricular ejection fraction, elevated levels of MR-proANP, MR-proADM, and CT-proET-1 were independently associated with the risk of cardiovascular death or heart failure (hazard ratios per 1-SD increase in log-transformed biomarker levels of 1.97, 1.48, and 1.47, respectively; P≤0.002 for each biomarker). These 3 biomarkers also significantly improved metrics of discrimination when added to a clinical model. Trandolapril significantly reduced the risk of cardiovascular death or heart failure in patients who had elevated levels of ≥2 biomarkers (hazard ratio, 0.53; 95% confidence interval, 0.36-0.80), whereas there was no benefit in patients with elevated levels of 0 or 1 biomarker (hazard ratio, 1.09; 95% confidence interval, 0.74-1.59; P(interaction)=0.012). CONCLUSIONS: In patients with stable coronary artery disease and preserved left ventricular ejection fraction, our results suggest that elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.


Subject(s)
Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/therapy , Coronary Disease/therapy , Adrenomedullin/blood , Aged , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Atrial Natriuretic Factor/blood , Biomarkers/blood , Coronary Disease/diagnosis , Death , Endothelin-1/blood , Female , Glycopeptides/blood , Heart Failure/diagnosis , Humans , Indoles/therapeutic use , Male , Middle Aged , Peptide Fragments/blood , Prognosis , Protein Precursors , Risk , Stress, Physiological , Stroke Volume
17.
Am J Infect Control ; 40(3): 267-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21868130

ABSTRACT

In this study examining public health workers' 2009 H1N1 and seasonal influenza vaccination uptake, a survey was conducted to assess flu vaccine acceptance, as well as behaviors and beliefs regarding acceptance, among public health workers in southeastern Tennessee. Factors found to be significantly associated with acceptance of the 2009 H1N1 vaccine were direct patient care, previous flu vaccination, vaccine safety concerns, and receipt of seasonal flu vaccine.


Subject(s)
Attitude of Health Personnel , Health Knowledge, Attitudes, Practice , Influenza Vaccines/administration & dosage , Influenza Vaccines/immunology , Influenza, Human/prevention & control , Patient Acceptance of Health Care/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Tennessee , Vaccination/statistics & numerical data , Young Adult
18.
Clin Chem ; 57(9): 1311-7, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21784767

ABSTRACT

BACKGROUND: Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD). METHODS: We measured plasma sPLA(2) activity at baseline in 3708 subjects in the PEACE randomized trial of trandolapril vs placebo in stable CAD. Median follow-up was 4.8 years. We used Cox regression to adjust for demographics, clinical risk factors, apolipoprotein B, apolipoprotein A1, and medications. RESULTS: After multivariable adjustment, sPLA(2) was associated with an increased risk of cardiovascular death, myocardial infarction, or stroke (adjusted hazard ratio Q4:Q1 1.55, 95% CI 1.13-2.14) and cardiovascular death or heart failure (1.91, 1.20-3.03). In further multivariable assessment, increased activity levels of sPLA(2) were associated with the risk of cardiovascular death, myocardial infarction, or stroke (adjusted hazard ratio 1.47, 95% CI 1.06-2.04), independent of lipoprotein-associated phospholipase A(2) mass and C-reactive protein, and modestly improved the area under the curve (AUC) beyond established clinical risk factors (AUC 0.668-0.675, P = 0.01). sPLA(2), N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T all were independently associated with cardiovascular death or heart failure, and each improved risk discrimination (P = 0.02, P < 0.001, P < 0.001, respectively). CONCLUSIONS: sPLA(2) activity provides independent prognostic information beyond established risk markers in patients with stable CAD. These data are encouraging for studies designed to evaluate the role of sPLA(2) as a therapeutic target.


Subject(s)
Coronary Disease/enzymology , Phospholipases A2, Secretory/blood , Aged , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Biomarkers/blood , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/mortality , Clinical Enzyme Tests , Coronary Disease/drug therapy , Double-Blind Method , Female , Heart Failure/diagnosis , Humans , Indoles/therapeutic use , Inflammation/blood , Inflammation/diagnosis , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/diagnosis , Necrosis , Predictive Value of Tests , Prognosis , Risk Assessment , Stroke/diagnosis
19.
Eur Heart J ; 32(11): 1390-7, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21345849

ABSTRACT

Aims There is increasing evidence that immune mechanisms are involved in the pathogenesis of heart failure (HF). The relationship between neopterin and the risk of HF has yet to be investigated on a large scale. We assessed the relationship between neopterin, a novel marker of monocyte activation, and risk of hospitalization for HF. Methods and results Among the subjects of Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial, 3946 had neopterin levels measured at study entry, on average 7 days after acute coronary syndrome (ACS). We assessed the relationship between neopterin and hospitalization for HF, and for death or HF over 2 years mean follow-up in a post hoc analysis using Cox regression models. Unadjusted hospitalization rates for HF increased across quartiles of neopterin, from 0.66 to 3.97 per 100 person-years. Per 1SD increment in log (neopterin), the adjusted risk of HF increased by 34% [hazard ratio (HR) 1.34, CI 1.10-1.64; P = 0.004]. Even after excluding individuals with a prior history of HF or recurrent ischaemic events, the relationship between neopterin and HF hospitalization remained significant. When added to a multivariable Cox model of HF-risk containing traditional risk factors, C-reactive protein and brain natriuretic protein (BNP), the further addition of neopterin significantly improved the HF-risk prediction model by likelihood ratio test analysis (P = 0.005), C-statistic (increasing from 0.743 to 0.773; P = 0.027), integrated discrimination improvement (IDI) analysis (P = 0.001), but not net reclassification improvement (NRI) analysis (P = 0.406). Similar results were obtained for the endpoint of death or HF. Conclusion Neopterin levels are an independent predictor of HF hospitalization, and improve risk prediction over and above conventional biomarkers.


Subject(s)
Acute Coronary Syndrome/complications , Heart Failure/diagnosis , Neopterin/blood , Acute Coronary Syndrome/drug therapy , Aged , Atorvastatin , Biomarkers/blood , Enzyme-Linked Immunosorbent Assay , Female , Heptanoic Acids/therapeutic use , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Pravastatin/therapeutic use , Proportional Hazards Models , Pyrroles/therapeutic use , Sensitivity and Specificity , Treatment Outcome
20.
Circulation ; 122(21): 2142-51, 2010 Nov 23.
Article in English | MEDLINE | ID: mdl-21060068

ABSTRACT

BACKGROUND: Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this population relative to cardiovascular outcomes. METHODS AND RESULTS: We evaluated 4162 patients enrolled in the PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial (acute coronary syndrome patients randomized to pravastatin 40 mg versus atorvastatin 80 mg). The average follow-up BP (systolic and diastolic) was categorized into 10-mm Hg increments. The primary outcome was a composite of death due to any cause, myocardial infarction, unstable angina requiring rehospitalization, revascularization after 30 days, and stroke. The secondary outcome was a composite of death due to coronary heart disease, nonfatal myocardial infarction, or revascularization. The relationship between BP (systolic or diastolic) followed a J- or U-shaped curve association with primary, secondary, and individual outcomes, with increased events rates at both low and high BP values, both unadjusted and after adjustment for baseline variables, baseline C-reactive protein, and on-treatment average levels of low-density lipoprotein cholesterol. A nonlinear Cox proportional hazards model showed a nadir of 136/85 mm Hg (range 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic) at which the incidence of primary outcome was lowest. The curve was relatively flat for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg. CONCLUSIONS: After acute coronary syndrome, a J- or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg, which suggests that too low of a pressure (especially <110/70 mm Hg) may be dangerous. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00382460.


Subject(s)
Acute Coronary Syndrome/drug therapy , Anticholesteremic Agents/administration & dosage , Blood Pressure/drug effects , Heptanoic Acids/administration & dosage , Myocardial Infarction/drug therapy , Pravastatin/administration & dosage , Pyrroles/administration & dosage , Acute Coronary Syndrome/mortality , Acute Coronary Syndrome/physiopathology , Adult , Aged , Anticholesteremic Agents/adverse effects , Atorvastatin , Blood Pressure/physiology , Female , Follow-Up Studies , Heptanoic Acids/adverse effects , Humans , Hypertension/mortality , Hypertension/prevention & control , Incidence , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/physiopathology , Pravastatin/adverse effects , Prognosis , Proportional Hazards Models , Pyrroles/adverse effects , Risk Factors , Thrombolytic Therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...